Pascual, Tomás
Oliveira, Mafalda http://orcid.org/0000-0001-9152-8799
Villagrasa, Patricia
Ortega, Vanesa
Paré, Laia
Bermejo, Begoña
Morales, Serafín http://orcid.org/0000-0001-7445-4193
Amillano, Kepa
López, Rafael http://orcid.org/0000-0003-1315-655X
Galván, Patricia
Canes, Jordi
Salvador, Fernando
Nuciforo, Paolo
Rubio, Isabel T.
Llombart-Cussac, Antonio
Di Cosimo, Serena
Baselga, José
Harbeck, Nadia http://orcid.org/0000-0002-9744-7372
Prat, Aleix http://orcid.org/0000-0003-2377-540X
Cortés, Javier http://orcid.org/0000-0001-7623-1583
Article History
Received: 13 March 2021
Accepted: 22 October 2021
First Online: 25 November 2021
Competing interests
: M.O. reports honoraria and consulting fees from Roche/Genentech, GSK, PUMA Biotechnology, AstraZeneca, Seattle Genetics, and Novartis; travel and accommodation paid by Roche, Pierre-Fabre, Novartis, GP Pharma, Grünenthal, and Eisai; and grant/Research Support (to the Institution) from AstraZeneca, Philips Healthcare, Genentech, Roche, Novartis, Immunomedics, Seattle Genetics, GSK, Boehringer-Ingelheim, PUMA Biotechnology, and Zenith Epigenetics outside the submitted work. P.V. has received honoraria as Speaker from Nanostring. B.B. reports honoraria as consultant/advisory role by Roche, MSD, Novartis, participating in speaker’s bureau of Roche, Novartis, MSD, Pfizer, Pierfabre and travel accommodations paid or reimbursed by Pfizer. R.L. reports grants and personal fees from Roche, grants and personal fees from Merck, personal fees from AstraZeneca, personal fees from Bayer, personal fees and non-financial support from BMS, personal fees from Pharmamar, personal fees from Leo, personal fees and non-financial support from Novartis, outside the submitted work. A.L.-C. reports stock, patents and intellectual property with MedSIR, consultant for AstraZeneca, Celgene, Novartis, Pfizer, Roche, Eli Lilly and TESARO, Daichi-Sanyo, SEAGEN, research funding from Eisai, Roche, Pfizer, Eli Lilly, MSD, GSK-TESARO, Pierre Fabre and meeting and travel fees from Roche, Celgene, Pfizer, Eli Lilly. S.D.C. reports honoraria and advisory board from Novartis and Pierre-Fabre outside the scope of this work. N.H. has declared personal honoraria for lectures and consulting: Astra Zeneca, Daiichi-Sankyo, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, Seattle Genetics. A.P. has declared personal honoraria from Pfizer, Novartis, Roche, MSD Oncology, Lilly and Daiichi Sankyo, travel, accommodations and expenses paid by Daiichi Sankyo, research funding from Nanostring Technologies, Roche and Novartis, consulting/advisory role for Nanostring Technologies, Roche, Novartis, Pfizer, Oncolytics Biotech, Amgen, Lilly, MSD, PUMA and Daiichi Sankyo, Inc. outside the submitted work. J. Cortés reports honoraria as consulting/advisor from Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme; honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung, Lilly, Merck Sharp&Dohme; research funding from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C, Queen Mary University of London, Seagen; and stock, patents and intellectual property from MedSIR. All other authors have declared no conflicts of interest.